London-based Tonic Life Communications has been appointed by Cardiorentis to help raise the profile of the Swiss biopharmaceutical company.
The communications agency has also been tasked with product PR for the acute heart failure treatment Ularitide, as it enters into phase III clinical trials.
Cardiorentis, which specialises in the development of treatments for cardiovascular diseases, was founded in 2010 and does not have an in-house communications division.
The global strategy will mainly focus on Europe and the US, and will work across corporate comms, medical congress support and data dissemination.
Leading the account will be Tonic Life associate director, Helen Swift, who will be working closely with Cardiorentis CEO Elmar Schnee.